Study of noise and spectroscopic performance of DEPMOSFET matrix prototypes for

Abstract The current generation of DEPMOSFET-based Active Pixel Sensor (APS) matrix devices has been developed to cope with the challenging requirements of the XEUS Wide Field Imager. The devices turned out to be a promising new imager concept for a variety of X-ray imaging applications. The devices combine excellent energy resolution, high-speed readout and low power consumption with the attractive feature of random accessibility of pixels. Sensor prototypes, built for row-wise readout, with 64 Â 64 pixels with a size of 75 Â 75 mm 2 each have been produced at the MPI semiconductor laboratory in Munich, and their performance has been studied in detail. A spectroscopic resolution of 128 eV has been measured, the readout noise is as low as 3:5 e À ENC. Here, measurements of the dependence of readout noise and spectroscopic resolution on the device temperature are presented.

NCALD as a potential predictive biomarkerfor the efficacy of platinum-basedchemotherapy in ovarian cancer - Supplementary Figure 3

Aim: Since reliable response predictors to platinum-based chemotherapy in ovarian cancer (OC) are scarce, we characterize NCALD as a predictive biomarker. Materials & methods: NCALD mRNA (n = 100) and protein (n = 102) expression was analyzed in OC samples and associated with patient outcome. A stable OC cell line knockdown was generated and cellular response to platinum was explored. Results: High NCALD mRNA and protein expression was significantly associated with longer overall patient survival (p = 0.037/0.002). Knockdown experiments revealed a significant association between cisplatin sensitivity and NCALD expression. Conclusion: Low NCALD expression was associated with reduced sensitivity to platinum-based chemotherapy. NCALD may be a new biomarker candidate to identify patients whomight benefit from platinum-based chemotherapy.</p

NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer - Supplementary Figure 2

Aim: Since reliable response predictors to platinum-based chemotherapy in ovarian cancer (OC) are scarce, we characterize NCALD as a predictive biomarker. Materials & methods: NCALD mRNA (n = 100) and protein (n = 102) expression was analyzed in OC samples and associated with patient outcome. A stable OC cell line knockdown was generated and cellular response to platinum was explored. Results: High NCALD mRNA and protein expression was significantly associated with longer overall patient survival (p = 0.037/0.002). Knockdown experiments revealed a significant association between cisplatin sensitivity and NCALD expression. Conclusion: Low NCALD expression was associated with reduced sensitivity to platinum-based chemotherapy. NCALD may be a new biomarker candidate to identify patients whomight benefit from platinum-based chemotherapy.</p

NCALD as a potential predictive biomarker for the efficacy of platinum-based - Supplementary Table 1

Aim: Since reliable response predictors to platinum-based chemotherapy in ovarian cancer (OC) are scarce, we characterize NCALD as a predictive biomarker. Materials & methods: NCALD mRNA (n = 100) and protein (n = 102) expression was analyzed in OC samples and associated with patient outcome. A stable OC cell line knockdown was generated and cellular response to platinum was explored. Results: High NCALD mRNA and protein expression was significantly associated with longer overall patient survival (p = 0.037/0.002). Knockdown experiments revealed a significant association between cisplatin sensitivity and NCALD expression. Conclusion: Low NCALD expression was associated with reduced sensitivity to platinum-based chemotherapy. NCALD may be a new biomarker candidate to identify patients whomight benefit from platinum-based chemotherapy.</p